Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.

Human vaccines

Volumn 1, Issue 1, 2005, Pages 37-42

  Halperin, Scott A ^a   Smith, Bruce ^a   Clarke, Kevin ^a   Treanor, John ^a   Mabrouk, Taoufik ^a   Germain, Marc ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS LINKING REAGENT; DRUG CARRIER; ETHER DERIVATIVE; GLYCEROL; INACTIVATED VACCINE; INFLUENZA VACCINE; LIPID; MALTODEXTRIN; POLYSACCHARIDE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BIOSYNTHESIS; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LIPID BILAYER; MALE; MIDDLE AGED; MUCOSAL IMMUNITY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CROSS-LINKING REAGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG CARRIERS; ETHERS; FEMALE; GLYCEROL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; LIPID BILAYERS; LIPIDS; MALE; MIDDLE AGED; POLYSACCHARIDES; VACCINES, INACTIVATED;

EID: 33645079448     PISSN: 15548600     EISSN: None     Source Type: Journal    
DOI: 10.4161/hv.1.1.1553     Document Type: Article

References (0)